Dayton Gastroenterology, Inc.
Industry / private company
Location:
Beavercreek, OH,
United States (USA) (US)
ISNI: -
THE NOX1/4 INHIBITOR GKT831 ACHIEVES CLINICALLY MEANINGFUL REDUCTIONS IN LIVER STIFFNESS, ATTENUATES CHOLESTASIS, AND IMPROVES QUALITY OF LIFE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (2019)
Huang JC, Invernizzi P, Dalekos GN, Nevens F, Van Vlierberghe H, Zigmond E, Andrade RJ, et al.
Conference contribution
Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial (2019)
Dalekos G, Invernizzi P, Nevens F, Hans VV, Zigmond E, Andrade RJ, Ben Ari Z, et al.
Conference contribution